EP Patent

EP3369732A1 — Androgen receptor modulating compounds

Assigned to Orion Oyj · Expires 2018-09-05 · 8y expired

What this patent protects

Compounds of formula (I) wherein R 1 to R 16 , A. B and E are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula ( I ) possess utility as tissue-selective androgen receptor modulators (SARM) and are particul…

USPTO Abstract

Compounds of formula (I) wherein R 1 to R 16 , A. B and E are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula ( I ) possess utility as tissue-selective androgen receptor modulators (SARM) and are particularly useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

Drugs covered by this patent

Patent Metadata

Patent number
EP3369732A1
Jurisdiction
EP
Classification
—
Expires
2018-09-05
Drug substance claim
No
Drug product claim
No
Assignee
Orion Oyj
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.